Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 16/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | LIPC | P11150 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30288293 | 0.78 | USP30 (0.44) | IRAK4 | |
| SCHEMBL30288268 | 0.76 | TLR7 (0.42) | IDH1LIPCLIPG | |
| SCHEMBL23367887 | 0.73 | CYP1A2 (0.41) | IRAK4CYP3A4ALOX5APIDH1 | |
| SCHEMBL30288239 | 0.73 | USP30 (0.39) | IRAK4ALOX5AP | |
| SCHEMBL17003433 | 0.72 | KDM1A (0.59) | — | |
| SCHEMBL17003431 | 0.72 | KDM1A (0.59) | — | |
| SCHEMBL23022787 | 0.70 | LMNA (0.48) | IRAK4CYP3A4ALOX5AP | |
| SCHEMBL23022736 | 0.69 | LMNA (0.47) | IRAK4CYP3A4ALOX5AP | |
| SCHEMBL27645050 | 0.69 | LMNA (0.47) | IRAK4CYP3A4ALOX5AP | |
| SCHEMBL23519500 | 0.68 | CHRM4 (0.39) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, MPST, CRAT | IRAK4 1706/4885CYP3A4 791/4885ALOX5AP 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.